Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-05T15:49:02.539Z Has data issue: false hasContentIssue false
  • English
  • Français

Duration of Untreated Illness as a Predictor of Treatment Response and Clinical Course in Generalized Anxiety Disorder

Published online by Cambridge University Press:  07 November 2014

A. Carlo Altamura ,
Bernardo Dell'Osso ,
Nazario D'Urso ,
Michela Russo ,
Sara Fumagalli  and
Emanuela Mundo
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction:

The aim of the present study was to investigate the impact of the duration of untreated illness (DUI)—defined as the time elapsing between the onset of generalized anxiety disorder (GAD) and the first adequate pharmacologic treatment—on treatment response and clinical course in a sample of subjects with GAD.

Methods:

One hundred patients with GAD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision criteria, were enrolled and their main demographic and clinical features collected. Patients were then treated with selective serotonin reuptake inhibitors or venlafaxine for 8 weeks in open-label conditions. Treatment response and other clinical variables were analyzed after dividing the sample into two groups according to DUI (DUI ≤12 months and DUI >12 months).

Results:

When the DUI was computed with respect to the first antidepressant treatment (DUI-AD), a higher improvement (Clinical Global Impressions-Severity of Illness scale) after the pharmacologic treatment was found in the group with a shorter DUI (analysis of variance with repeated measures: time effect F=654.975, P<.001; group effect: F=4.369, P=.O39). When computed with respect to the first treatment with benzodiazepines (DUI-BDZ), the two groups did not show any significant difference in treatment response (time effect: F=652.183, P<.001; group effect: F=0.009, P=.924). In addition, patients with a longer DUI (DUI-BDZ or DUI-AD) showed an earlier age at onset, a longer duration of illness and a higher rate of comorbid psychiatric disorders with onset later than GAD.

Conclusion:

Results from this preliminary study seem to suggest that a shorter DUI-AD may determine a better response to pharmacologic treatment in patients with GAD, and that a longer DUI (DUI-BDZ and DUI-AD) may be associated to a worse clinical course. Further investigation on the relationship between DUI and GAD is needed.

Type
Original Research
Information
CNS Spectrums , Volume 13 , Issue 5 , May 2008 , pp. 415 - 422
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Lieb, R, Becker, E, Altamura, AC. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005;15:445–452.Google Scholar
2.Rynn, MA, Brawman-Mintzer, O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr. 2004;9:716–723.CrossRefGoogle ScholarPubMed
3.Flint, AJ. Generalized anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging. 2005;22:101–114.CrossRefGoogle ScholarPubMed
4.Ninan, PT. Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 19):5–10.Google ScholarPubMed
5.Wittchen, HU, Kessler, RC, Beesdo, K, Krause, P, Hofler, M, Hoyer, J. Generalized anxiety and depression in primary care: prevalence, recognition and management. J Clin Psychiatry. 2002;63:24–34.Google ScholarPubMed
6.Kapczinski, F, Lima, MS, Souza, JS, Schmitt, R. Antidepressants for generalized anxiety disorder. Cochrane Database SystRev. 2003;CD003592.Google Scholar
7.Rickels, K, Rynn, M, lyengar, M, Duff, D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry. 2006;67:41–47.CrossRefGoogle ScholarPubMed
8.Stahl, SM, Ahmed, S, Haudiquet, V. Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. CNS Spectr. 2007;12:703–711.CrossRefGoogle ScholarPubMed
9.Baldwin, DS, Polkinghorn, C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol. 2005;8:293–302.Google Scholar
10.Guest, JF, Russ, J, Lenx-Smith, A. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalized anxiety disorder in the United Kingdom. Eur J Health Econ. 2005: January 29 [Epub ahead of print].Google Scholar
11.Kim, TS, Pae, CU, Yoon, SJ, et al.Comparison of venlfaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2006;60:347–351.CrossRefGoogle Scholar
12.Perkins, DO, Gu, H, Boteva, K, Lieberman, JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785–1804.CrossRefGoogle ScholarPubMed
13.Lieberman, JA, Sheitman, BB, Kinon, BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 1997;17:205–229.CrossRefGoogle ScholarPubMed
14.Altamura, AC, Bassetti, R, Sassella, F, Salvadori, D, Mundo, E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res. 2001;52:29–36.Google Scholar
15.Goldberg, JF, Ernst, CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985–991.Google Scholar
16.Altamura, AC, Dell'Osso, B, Mundo, E, Dell'Osso, L. Duration of untreated illness in major depressive disorder: a naturalistic study. Int J Clin Pract. 2007;61:1697–1700.Google Scholar
17.Mundo, E, Santini, A, Salvadori, D, Altamura, AC. Duration of untreated illness (DUI) and clinical course in bipolar disorder. Paper presented at: Annual Meeting of the American Psychiatric Association; May 21-26. 2005: Atlanta, Ga.Google Scholar
18.Altamura, AC, Dell'Osso, B, Vismara, S, Mundo, E. May duration of untreated illness influence the long-term course of major depressive disorder? Eur Psychiatry. 2008;23:92–96.Google Scholar
19.Altamura, AC, Santini, A, Salvadori, D, Mundo, E. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr Dis Treat 2005;1:1345–1347.Google ScholarPubMed
20.Pollack, MH, Meoni, P, Otto, MW, Simon, N, Hackett, D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short-and long-term studies. J Clin Psychopharmacol. 2003;23:250–259.Google Scholar
21.Diagnostic and Statistical Manual for Mental Disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
22.Allgulander, C, Bandelow, B, Hollander, E, et al.WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003;8:53–61.Google Scholar
23.First, MB, Spitzer, RL, Gibbon, , et al.Structured Clinical Interview for DSM-IV Axis I (SCID-I), clinician version. Washington, DC: American Psychiatric Press; 1997.Google Scholar
24.Guy, W. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education and Welfare; 1976:218–222.Google Scholar
25.De Bellis, MD, Casey, BJ, Dahl, RE, et al.A pilot study of amygdala volumes in pediatric generalized anxiety disorder. Biol Psychiatry. 2000;48:51–57.CrossRefGoogle ScholarPubMed
26.De Bellis, MD, Keshavan, MS, Shifflett, H, et al.Superior temporal gyrus volumes in pediatric generalized anxiety disorder. Biol Psychiatry. 2002;51:553–562.CrossRefGoogle ScholarPubMed
27.Milham, MP, Nugent, AC, Drevets, WC, et al.Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation. Biol Psychiatry. 2005;57:961–966.CrossRefGoogle ScholarPubMed
28.Etkin, A, Wager, TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476–1488.CrossRefGoogle ScholarPubMed
29.Milad, MR, Rauch, SL. The role of the orbitofrontal cortex in anxiety disorders. Ann N Y Acad Sci. 2007;1121:546–561.CrossRefGoogle ScholarPubMed
30.Sareen, J, Jagdeo, A, Cox, BJ, et al.Perceived barriers to mental health service utilization in the United States, Ontario, andthe Netherlands. Psychiatr Serv. 2007;58:357–364.Google Scholar